Dietary supplement Nattokinase NKCP

Nattokinase is an enzyme, also known as a fibrinolytic enzyme, that plays an important role in breaking down fibrin, the main component of blood clots. This is an important process for maintaining normal blood viscosity and preventing excessive clotting that can lead to cardiovascular disease.

Structurally, nattokinase is a protein that is composed of amino acids, and its specific functionality is achieved as a result of its tertiary structure. It is part of the group of serine proteinases, which are a class of enzymes responsible for the hydrolysis of peptide bonds in proteins.

Nattokinase is synthesized in various tissues and organisms, such as bacteria, fungi, and humans. This exoenzyme is secreted into the extracytoplasm and can be secreted into the environment or the bloodstream.

The function of nattokinase is related to the degradation of fibrin, which occurs through the hydrolysis of specific bonds in the fibrinogen and fibrin molecules. This contributes to the dissolution of blood clots and facilitates normal blood flow. The process of fibrinolysis, which is activated by nattokinase, is regulated by complex mechanisms and involves the activation of proteolytic enzymes such as activated factor XII, thrombin and tissue plasminogens.

In addition to its role in breaking down fibrin, nattokinase is also known to have other potential functions. Some research suggests that it may be involved in regulating the immune system, maintaining normal blood viscosity, and clearing excess proteins from the body.

Nattokinase has a wide range of medical applications. It is used in the treatment of thrombosis, heart attacks, and other cardiovascular diseases. In addition, nattokinase is being studied for its potential applications in various areas such as breaking down fibrous tissues, improving circulation, and aiding digestion.

Daiwa's NKCP (Nattokinase Containing Product) is a dietary supplement manufactured by the Japanese pharmaceutical company Daiwa Pharmaceutical. This product is known for containing nattokinase (NK), which is a fibrinolytic enzyme produced from soybeans, which are known in Japanese cuisine as natto.

NKCP Daiwa is available in tablet form and is intended for oral administration. The main active ingredient in the product is nattokinase, which is known for its potential benefits for the cardiovascular system. Nattokinase contributes to the breakdown of fibrin, the main component of blood clots. This helps maintain normal blood viscosity and prevent excessive clotting, which can lead to cardiovascular problems such as thrombosis and heart attack.

NKCP Daiwa is standardized to ensure consistency in nattokinase content in each capsule. This allows for easier dosing and control of product intake. The dosage and regimen of the product are usually determined by the manufacturer, taking into account recommendations for the age, gender and health status of the user.

NKCP Daiwa is intended to be used as a food supplement and should not be used as a substitute for a varied and balanced diet. Before starting to use the product, it is always advisable to consult a healthcare professional or pharmacist, especially if you have any significant health problems or are taking other medications.

It is important to note that the effects of NKCP Daiwa may vary from person to person and some people may benefit more from taking it than others. Always follow the manufacturer's instructions and recommendations regarding dosage, route of administration and duration of use of the product.

Features:

– NKCP is extracted from Bacillus subtilis var. natto and is free of the undesirable odor and viscous texture of natto. •

– The purpose of NKCP is threefold. To function as (1) an anticoagulant (2) a thrombolytic and (3) a blood thinner. •

– Most of the vitamin K2 is eliminated, making it less antagonistic to other drugs such as warfarin. •

– NKCP is standardized to contain specific levels of proteolytic enzymes secreted by Bacillus subtilis var. natto. •

– The main functional enzyme (protease) is stable at pH 6.0-10.0 and at temperatures of 60℃ or lower. •

– The safety of NKCP has been confirmed in many animal and human studies. •

– The manufacturing process for this purified filtrate from Bacillus subtilis var. natto culture is registered under patent number 3532503 in Japan. Recommended daily dose 125-500 mg/day

– Single dose LD50 >5,000 mg/kg

– NOAEL after repeated administration Males: > 1325 mg/kg body weight/day Females: > 1,541 mg/kg body weight/day

– Mutagenicity Negative (± metabolic activation)

– Antigenicity (guinea pigs) Negative for active systemic anaphylactic reaction (ASA) and passive cutaneous anaphylactic reaction (PCA)

– Effect on bleeding time (rats) In rats given NKCP orally, a 0.5 mm incision was made at the tip of the tail after 1 hour to measure bleeding time.

– NKCP at 300 mg/kg does not prolong bleeding time.

– Interaction with warfarin (rats) NKCP at 250 mg/kg was administered into the duodenum by the in situ loop method in rats, in which bleeding time was delayed by warfarin treatment and blood collected after 6 hours was measured for coagulation time. Warfarin treatment significantly prolonged coagulation time compared to the control group, but no additional coagulation delay was observed in the warfarin + NKCP treatment group compared to the warfarin treatment group.

– Long-term use (humans): Twenty-three healthy adults received NKCP 250 mg/day for 12 weeks and no clinically significant adverse reactions were observed. There were no statistically significant changes in hematological or biochemical tests. Five healthy adults received NKCP 750 mg/day for 6 consecutive weeks to study and monitor changes in laboratory test values (hematological tests, biochemical tests and coagulation/fibrinolysis parameters) and adverse events. As a result, ELT was shortened, t-PA decreased and thromboplastinogen activity test (TAT) increased, but all values were within normal limits. In addition, no adverse events were observed, suggesting the safety of NKCP.

– High-dose administration (humans) Eight healthy adults received NKCP at 1250 mg/day for 7 consecutive days. Observation of clinical signs and laboratory tests were used to assess the safety of NKCP. No clinically significant adverse reactions were observed. No abnormal changes in hematological or biochemical tests were observed.

Daily intake:

Take 1 to 2 tablets once a day after meals.

Directions:

Store in a dry and cool place, keep out of reach of children.

Consult your doctor if you are taking medications related to thrombosis or blood circulation.

Manufacturer: Daiwa Pharmaceutical Co., Ltd., Japan